Research
FORUM TRANSCRIPT

Influenza Vaccines – Next-generation mRNA Vaccines & Market Update – Part 1 – 7 October 2021

  • Public Equity
  • Healthcare
  • North America
PREMIUM

Specialist

Former VP at GlaxoSmithKline plc

Agenda

  • Key trends impacting the flu vaccine market, including coronavirus and entrance of mRNA vaccine technology
  • Approved flu vaccines similar to those from Sanofi (NASDAQ: SNY), GlaxoSmithKline (NYSE: GSK) and Seqirus (ASX: CSL), discussing market demand and challenges
  • Entrance and potential of mRNA technology for flu vaccines in light of developments from Sanofi and Translate Bio and Pfizer (NYSE: PFE)
  • Key market developments, including Novavax's (NASDAQ: NVAX) NanoFlu and potential for bundling and/or combining the flu and coronavirus vaccines
  • Outlook for Q4 2021 and beyond

Questions

For access to this and thousands of other Transcripts, request a free trial

Request A Demo